These are likely to involve harnessing of the innate or adaptive immune mechanisms to overcome immune tolerance or T cell exhaustion in eliminating myeloid malignancies, including those driven by EVI1 dysregulation. This evidence concerns the gene RUNX1 and myeloid neoplasm.